| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IP | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FGFR-2; K-sam; KGFR; CD332; FGFR2; BEK; KGFR; KSAM;;FGFR2 |
| WB Predicted band size | Calculated MW: 92 kDa ; Observed MW: 145 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human FGFR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇与FGFR2抗体相关的代表性文献摘要(基于真实研究虚构示例)：
1. **"Selective FGFR2 blockade by monoclonal antibody FPA144 demonstrates antitumor activity in FGFR2-altered tumors"**
- Author: Smith JD, et al.
- 摘要：开发了一种选择性靶向FGFR2的单克隆抗体FPA144.在FGFR2基因扩增或突变的胃癌和乳腺癌异种移植模型中显著抑制肿瘤生长，并通过阻断配体依赖性信号通路诱导细胞凋亡。
2. **"Antitumor efficacy of a novel anti-FGFR2 antibody-drug conjugate in endometrial cancer models"**
- Author: Zhang L, et al.
- 摘要：报道了一种FGFR2靶向的抗体-药物偶联物(ADC)，在FGFR2过表达的子宫内膜癌模型中展现出强效抗肿瘤活性，其机制包括内吞药物释放和DNA损伤诱导。
3. **"Resistance mechanisms to FGFR2-targeted therapies in cholangiocarcinoma"**
- Author: Brown CR, et al.
- 摘要：分析了胆管癌患者接受FGFR2抗体治疗后产生获得性耐药的分子机制，发现MET通路激活和FGFR2胞外域突变是主要逃逸途径，并提出联合用药策略。
(注：以上为模拟摘要，实际文献需通过PubMed/Google Scholar检索关键词"FGFR2 antibody therapy"或具体药物名如bemarituzumab获取。)
Fibroblast Growth Factor Receptor 2 (FGFR2) is a transmembrane tyrosine kinase receptor critical for regulating cell proliferation, differentiation, migration, and survival during embryonic development, tissue repair, and disease. Dysregulation of FGFR2 signaling, caused by gene amplification, mutations, or aberrant expression, is implicated in various cancers (e.g., breast, gastric, and endometrial cancers) and developmental disorders (e.g., craniosynostosis syndromes). FGFR2-targeting antibodies are engineered to modulate FGFR2 activity, either by blocking ligand binding, inhibiting receptor dimerization, or promoting receptor internalization. These antibodies serve as valuable tools for studying FGFR2’s biological roles and as therapeutic agents. In oncology, FGFR2 inhibitors, including monoclonal antibodies and small-molecule tyrosine kinase inhibitors, are being explored to counteract tumor growth and metastasis driven by FGFR2 overexpression or mutations. Additionally, FGFR2 antibodies are used in diagnostics to detect receptor expression patterns in tissues, aiding cancer subtyping and prognosis. Challenges in therapeutic development include addressing isoform-specificity (FGFR2 has multiple splice variants), minimizing off-target effects, and overcoming drug resistance. Recent advances in antibody engineering, such as bispecific antibodies or antibody-drug conjugates, aim to enhance precision and efficacy. Overall, FGFR2 antibodies represent a promising avenue for both understanding FGFR2-related pathologies and developing targeted therapies.
×
